This case addresses the accounting for the relationship between a pharmaceutical company and a research and development entity that it created and for which it raised operating funds via a limited private offering. After the offering, the pharmaceutical company does not own any of the R&D entity's stock. However, the stock is callable for a fixed period by the pharmaceutical company and the operating agreements between the two entities leave little room for the R&D company to make any substantive decisions on its own, or to direct its current and future operations. Most of the questions in the case deal with the issue of whether control exists, the impact of that answer on the consolidated financial statements, and the details and costs of calling the stock.

This content is only available as a PDF.
You do not currently have access to this content.